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SUMMARY 
(1) The evidence for a role of prolactin in the premenstrual syndrome is discussed in this 
review. (2) The timing of the onset and offset of both physical and psychological dysphoric 
symptoms corresponds with the luteal elevation and menstrual decrease of serum prolactin 
levels. (3) Women with premenstrual symptoms have been shown to have high prolactin levels 
throughout the menstrual cycle and especially in the premenstruum. (4) Suppression of pro- 
lactin secretion with bromocriptine is reported to be effective in preventing both physical and 
psychological premenstrual symptoms. (5) The mode of action of bromocriptine requires 
further study to exclude possible direct central nervous system effects of the drug, independent 
of its prolactin-suppressing action. (6) Indirect evidence for a role of prolactin in the prernen- 
strual syndrome comes from (a) the actions of prolactin in causing renal retention of water, 
sodium and potassium; (b) the interactions of prolactin with lithium (which is reported to 
relieve premenstrual symptoms in some patients); some of the other reported treatments also 
may suppress prolactin secretion or antagonize its peripheral effects. (7) Prolactin may interact 
with the ovarian hormones to cause specific types of dysphoric symptoms. High prolactin 
levels associated with low estrogen levels may cause depressive symptoms. High prolactin 
levels associated with low progesterone levels may cause symptoms of anxiety or irritable 
hostility. (8) Interactions of prolactin with the ovarian hormones may also help to account for 
some related clinical states--mid-cycle mood elevations, elation in late pregnancy, post- 
partum depression and dysphoric menopausal symptoms. 
INTRODUCTION 
IN A PRECEDING paper  (Steiner & Carroll,  1977) we reviewed the varied manifestations o f  
the premenstrual  syndrome,  the m a n y  suggested theories concerning its etiology and the 
range o f  unsatisfactory treatments recommended for it. One way of  integrating many  o f  
these observations with the physiology of  the menstrual  cycle is to propose  that  prolactin 
plays a major  role in the premenstrual  syndrome. This idea was first advanced by Hor rob in  
(1973a) and recent findings have appeared which strongly support  his theory. In  this paper  
we shall review the several lines o f  evidence for  a role o f  prolactin (PRL) in the premenstrual  
syndrome and possibly in other clinical states as well. 
Direct evidence 
I. The timing of  the premenstrual  symptoms coincides with the late luteal elevation of  
plasma P R L  levels. The reported studies o f  P R L  changes during the menstrual  cycle were 
reviewed in the previous paper,  and it was pointed out  that  some women have significantly 
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higher PRL levels during this phase than during the follicular phase (Franchimont, Dourcy, 
Legros, Reuter, Vrindts-Gevaert, Van Cauwengerge & Gaspard, 1976; Vekemans, Delvoye, 
L'Hermite & Robyn, 1977). Furthermore, the elevated PRL levels do not drop until the 
onset of menstruation, which coincides with the relief of premenstrual symptoms. By 
contrast, the levels of renin, angiotensin II, aldosterone, estrogens and progesterone decrease 
several days earlier, at about the time the symptoms first appear. 
2. Women with high premenstrual ratings of dysphoria have significantly elevated PRL 
levels during the premenstruum (Guy E. Abraham, personal communication, 1976). This 
report has been documented further by Halbreich, Assael, Ben-David & Borstein (1976). In 
their study, women with premenstrual symptoms were compared with women who reported 
no premenstrual difficulties. The symptomatic women had higher PRL levels than the 
control women at all phases of the cycle; they also had significantly greater proportionate 
increases of PRL levels during the premenstruum. The authors commented that the high 
PRL levels in the symptomatic women could be due to the "stress" of their symptoms, but 
other lines of evidence to be discussed below make this seem unlikely. 
3. The treatment results obtained with bromocriptine (which suppresses PRL secretion) 
argue strongly for a major influence of PRL in the premenstrual syndrome (Benedek- 
Jaszmann & Hearn-Sturtevant, 1976). These authors believe that they "may have found the 
key to the aetiology of this syndrome." When PRL secretion was suppressed by bromo- 
criptine over 90 ~ of their subjects obtained complete relief from premenstrual symptoms 
for up to 11 months. No other treatment has ever been claimed to approach this level of 
effectiveness. This study contained only a small double-blind crossover controlled investi- 
gation, together with two open investigations. A more extensive controlled clinical trial will 
be needed to confirm this report. The clinical features rated in the study were "1. Breast 
swelling, discomfort and pain with or without discharge from the nipples. 2. Abdominal 
discomfort and swelling. 3. Migraine. 4. Weight gain and edema. 5. Psychological disturb- 
ances including lability of mood, depression and tiredness". 
One remarkable aspect of the results is that improvement was observed in all of these 
areas. While the beneficial effect of bromocriptine on the physical symptoms may be due to 
PRL suppression, the psychological benefit could possibly have resulted from direct actions 
of bromocriptine on the central nervous system. For example, bromocriptine, being a 
dopamine receptor agonist, is used to treat Parkinson's disease (Thorner, McNeilly, Hagan 
& Besser, 1974; Cooke, Foley, Lenton, Preston, Millar, Jenkins, Obiekwe, McNeilly, 
Parsons & Kennedy, 1976; Calne, Teychenne, Claveria, Eastman, Greenacre & Petrie, 
1974). Since other dopamine agonists and suppressors of PRL such as L-dopa and piribedil 
also have behavioral effects (Chase & Shoulson, 1975), further strategies will need to be 
developed to distinguish the PRL-suppressive action of bromocriptine from its possible 
direct central behavioral effects in women treated for the premenstrual syndrome. An 
extensive single case study reported by Horrobin, Mtabaji, Kermali, Manku & Nassar 
(1976) also suggests that bromocriptine is effective against both physical and behavioral 
premenstrual symptoms. 
Bromocriptine is an amino acid ergot alkaloid which is known to be a specific agonist of 
dopaminergic receptors (Fuxe, Agnati, Hokfelt, Jonsson, Lidbrink, Ljungdahl, Lofstrom 
& Ungerstedt, 1975). It suppresses human prolactin secretion not only in the post-partum 
ROLE OF PROLACTIN IN PREMENSTRUAL DYSPHORIA 173 
period and in the galactorrhea syndromes but also throughout the menstrual cycle. It is 
also effective in preventing the nocturnal pulsatile release of prolactin (DelPozo, 1973). 
Other dopamine agonists which suppress prolactin secretion in man include L-dopa 
(Malarkey, Jacobs & Daughaday, 1971), apomorphine (Martin, Lal, Tolis & Friesen, 1974), 
dopamine itself (Massara, Camanni, Belforte & Molinatti, 1976), piribedil (Chase & 
Shoulson, 1975) and two other ergot derivatives, namely ergonovine (Shane & Naftolin, 
1974) and lergotrile (Lilly 83636) (Lemberger, Crabtree, Clemens, Dyke & Woodburn, 
1974). L-Dopa, apomorphine and dopamine have durations of action which are generally 
too short to make them clinically useful. The most promising agents at the clinical level for 
long-term suppression of prolactin secretion are bromocriptine, lergotrile and piribedil. So 
far, only bromocriptine has actually been used in patients with premenstrual syndromes. 
We should expect any one of these three agents to be effective however. 
Indirect evidence 
1. Water and electrolyte retention. We noted in the previous paper that premenstrual 
edema is frequently associated with premenstrual dysphoria. There is general agreement 
that women gain 1-2 kg weight premenstrually and lose it in a diuresis when menstruation 
occurs (Israel, 1967). Along with the water retention there is also retention of both sodium 
(Na) and potassium (K). The sodium retention predominates, however, so that urinary 
Na/K ratios increase. A woman with very severe premenstrual edema was described by 
Horrobin (1973a). She had profound oliguria and sodium retention, together with less 
severe but marked potassium retention, and a premenstrual weight gain of 6-10 kg. The 
association of both K and Na retention is remarkable, since the mineralocorticoids (des- 
oxycorticosterone, aldosterone and corticosterone) characteristically promote K loss in 
exchange for Na retention. The only hormone capable of causing retention of water, K and 
Na is said to be prolactin (Horrobin, 1973a). In addition, PRL potentiates the renal effects 
of aldosterone and of anti-diuretic hormone (ADH) (Horrobin, 1973b). Other evidence 
suggests that PRL may be required for the rise in aldosterone levels following Na deprivation 
or furosemide administration (Relkin & Adachi, 1973; Edwards, Thorner, Miall, A1-Dufaili, 
Hauber & Besser, 1975). It is clear that PRL has important interactions with the mineralo- 
corticoids and their effects on the kidney. Prolactin is known to be an important osmo- 
regulatory hormone in several lower vertebrate species (Nicoll & Bern, 1972) and it has 
been proposed recently to have an antidiuretic action in man (Carey & Johanson, 1976). 
Human PRL secretion has further been shown to respond to induced changes in serum 
osmolality (Buckman & Peake, 1973). 
Horrobin's group has shown that lithium can antagonize the renal actions of aldosterone 
and antidiuretic hormone (ADH) in rats, and that the addition of ovine PRL then over- 
comes this effect of lithium (Mtabaji, Manku & Horrobin, 1975). A similar interaction 
between lithium and PRL has been shown in the responses of vascular tissue to norepine- 
phrine (Horrobin et al., 1976). The interactions of lithium with the renal effects of PRL in 
man have not been studied directly. 
2. Many of the treatments proposed for the premenstrual syndrome may antagonize 
either the secretion of PRL or its effects. The case of bromocriptine was discussed above. 
The clinical trials with lithium were reviewed in the previous paper and the interactions 
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between lithium and PRL were discussed above, There is some evidence that lithium blocks 
the tissue effects of PRL. On the other hand, there is little evidence that lithium can act like 
bromocriptine to block the release of PRL (Epstein, Sagel, Zabow, Pimstone & Vinik, 
1975; Smythe, Brandstater & Lazarus, 1975; Meltzer & Fang, 1976). It is also possible 
that lithium could antagonize premenstrual fluid and electrolyte retention by virtue of its 
diuretic and anti-ADH actions (Baer, 1973). Diuretic agents may be helpful for similar 
reasons, as may the aldosterone antagonist, spironolactone. The failure of these latter two 
treatments to be consistently useful, however, suggests that it is not the water and electrolyte 
retention per se which causes the premenstrual symptoms, but rather a CNS action of the 
elevated prolactin levels. Horrobin (1973c) has commented on the possibility that furo- 
semide blocks the renal actions of PRL. 
Pyridoxine is a relative newcomer in the treatment of premenstrual syndromes and was 
believed to be effective in at least some women by an effect on tryptophan metabolism 
(Baumblatt & Winston, 1970; Stokes & Mendels, 1972). Most of these reports were anec- 
dotal but some women did appear to benefit from pyridoxine treatment in a dramatic 
fashion. It is possible that, in these subjects, pyridoxine caused suppression of PRL sec- 
retion. Recent evidence indicates clearly that pyridoxine does have this effect when given in 
large doses to human subjects (Delitala, Masala, Alagna & DeVilla, 1976). 
It is noteworthy that, of all the drugs which have been recommended at one time or 
another for the treatment of premenstrual dysphoria, phenothiazines are never mentioned in 
the literature. If there is any basis to the postulated role of PRL in the premenstrual syn- 
dromes, then one would expect phenothiazines to worsen the symptoms, by virtue of their 
elevation of serum PRL levels (Meltzer & Fang, 1976). 
3. Other indirect evidence. Another indirect support for a proposed role of PRL in pre- 
menstrual dysphoria comes from a comparison of the endocrine changes which occur 
premenstrually and in the post-partum period. At the time when the "post-partum blues" 
occur (typically about the third day after delivery) (Yalom, Lunde, Moos & Hamburg, 
1968), PRL levels are very high, while progesterone and estrogen levels have declined 
precipitously (Yuen, Keye & Jaffe, 1973; Jaffe, Yuen, Keye & Midgley, 1973). This is 
similar to the pattern seen in the premenstruum. This comparison suggests that high levels 
of PRL may have behavioral effects in humans, which can be antagonized by estrogens and/or 
progesterone. Anecdotal support for this behavioral effect of PRL comes from Horrobin 
(1973a) who describes his reaction to a prolactin injection thus: "The first time I injected 
prolactin into myself, my wife accused me of being lethargic and irritable, i.e. 'premen- 
strual', this first aroused my interest in the syndrome." At that time Horrobin outlined the 
evidence for a role of PRL in the premenstrual syndromes, and he correctly predicted that 
bromocriptine would "produce a striking improvement in women with the syndrome." One 
other piece of anecdotal evidence comes from McNeilly (1973), who reported that women 
with galactorrhoea and hyperprolactinaemia who were treated with bromocriptine "feel 
very much better in themselves" while receiving the drug. One further line of indirect 
evidence is that a strong sensation of thirst is frequently noted in the premenstrual syn- 
dromes. Injection of prolactin into humans consistently provokes the sensation of thirst 
(Horrobin, 1973a; Greenwood, 1973). 
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RELATION OF PROLACTIN TO OVARIAN HORMONES AND DYSPHORIA 
Most of the original theories about the premenstrual syndromes focused upon changes in 
ovarian estrogen or progesterone secretion. At various times it has been suggested that the 
premenstrual syndrome is caused either by (1) a relative lack of progesterone ("progesterone 
withdrawal") or (2) a relative lack of estrogen ("estrogen withdrawal"). Laboratory evidence 
for both of these patterns has been reported (Smith, 1975). 
A careful reading of these reports suggests that the confusion and disagreement between 
these two schools of thought may result from variations in the definition of "premenstrual 
depression" by different investigators. For example, Dalton (1971), who emphasizes the 
progesterone deficiency idea, and who claims good results in many cases with progesterone 
treatment, appears to be describing mostly a syndrome of premenstrual irritability and 
hostility, rather than depression as such. Similarly, Backstrom & Carstensen (1974) pre- 
sented impressive evidence for low progesterone levels in women with "premenstrual 
anxiety." Cullberg (1972) also concluded that some cases of "premenstrual irritability" 
were due to estrogen dominance (i.e. a relative lack of progesterone). 
On the other hand, Smith and his associates, who carefully selected a group of women 
with "premenstrual depression, as opposed to irritability, edema or anxiety" found minimal 
differences in plasma progesterone levels, and no improvement with progesterone injections 
(Smith, 1975). Similarly, Abraham makes a careful distinction between premenstrual 
depression and premenstrual hostility-irritability. The depressed women have low plasma 
estrogens in the luteal phase, resulting in a high progesterone/estrogen ratio. These women 
respond well to treatment with estrogens. The irritable-hostile women, on the other hand, 
have low plasma progesterone, as in the report by Backstrom & Carstensen (1974), and 
these women respond well to progesterone. Further, the irritable women do poorly with, or 
are made worse by treatment with estrogens. They also have especially high plasma cortico- 
sterone/cortisol ratios in the luteal phase (Schwartz & Abraham, 1975; Guy E. Abraham, 
personal written and oral communications, 1976). 
These recent findings, in combination with the many early speculations, confirm that the 
ovarian hormones do have a role in the production of premenstrual dysphoria. With better 
differentiation between the depressed group on the one hand and the irritable-anxious- 
hostile group on the other hand, the following scheme suggests itself: Premenstrual depression 
may result from high levels of prolaetin, in conjunction with low levels of estrogen, or relative 
progesterone dominance. Premenstrual irritability-hostility may result from high levels of 
prolactin in association with low levels of progesterone. In other words, it may be the inter- 
action of the ovarian hormone changes with elevated prolactin levels which causes the two 
major types of premenstrual dysphoria. In his comprehensive review of the widespread 
physiological roles of prolactin Nicoll (1974) emphasized this important aspect of pro- 
lactin's actions. He summarized the evidence by stating that PRL has a major role "of 
modifying the responsiveness of various organs to the influence of other hormones--a 
broad spectrum conditioner of the hormonal sensitivity of a wide variety of vertebrate 
organs." These conclusions of Nicoll are consistent with the interactions we are proposing 
between PRL and the ovarian hormones in the production of premenstrual symptoms. 
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RELATION TO OTHER CLINICAL STATES 
An extension of these proposed endocrine-affective relationships may be added by 
reference to several other clinical phenomena, which have until now been difficult to fit into 
a coherent framework. 
1. Mid-cycle mood elevations. Since the early reports of Benedek & Rubenstein (1939) 
it has been known that women at the time of ovulation tend to be happy, alert, and outer- 
directed, with a peak in ego integration coinciding with the estrogen peaks. In the early 
luteal phase the features of passivity, narcissism and inner-directedness appear, while in the 
late luteal phase they reported finding their subjects aggressive, tense and anxious. These 
descriptions obtained from psychoanalytic material have been confirmed by Bardwick and 
her associates who studied spontaneous verbal output by the Gottschalk technique (Bard- 
wick, 1976). During this mid-cycle phase plasma estrogen and prolactin levels peak con- 
currently, as described earlier. These findings tend to suggest that high PRL levels in 
association with high estrogen levels result in positive rather than negative affective change. 
2. Mood elevations in mid- to late pregnancy. Elation during late pregnancy is acommon 
occurrence. Dalton (1971) found that it was present in 64~o of women with puerperal 
depression, compared with only 26 ~o of normal women. Patients who experienced the 
sequence of euphoria in pregnancy followed by post-partum depression described their 
pregnant state in such terms as "blissful", "never so well in my life", "walked miles with 
ease" and "boundless energy". Once again, during late pregnancy PRL levels are very 
high, together with very high estrogen and progesterone levels. 
Thus, from these two examples, one might speculate that high levels of  both prolactin and 
estrogen result in positive or euphoric affective change. 
3. Postpartum depression. The endocrine changes which occur after delivery are similar 
to those occurring premenstrually, and the absolute magnitude of hormonal changes is 
greatly exaggerated. When the post-partum blues occur (usually during the first week after 
childbirth), the PRL levels are still well above normal values, while the levels of progesterone 
and estrogen have dropped precipitously (Yuen et al., 1973; Jaffe et al., 1973). Post-partum 
mood change frequently occurs in women who also experience premenstrual dysphoria and 
mood elevations during pregnancy (Dalton, 197 l). 
4. Depression or irritability in post-menopausal women. There have been a number of 
reports that monthly mood swings occur in some women following their menopause, or 
after ovariectomy (Smith, 1975). Other women experience more pervasive anxiety and 
irritability during the menopause. At this time both estrogen and progesterone levels are 
much reduced (Abraham & Maroulis, 1975), while circulating prolactin levels are still at 
pre-menopausal levels and continue to show wide circadian fluctuations (Rozencweig, 
Heuson, Bila, L'Hermite & Robyn, 1973; Robyn, Delvoye, Nokin, Vekemans, Badawi, 
Perez-Lopez & L'Hermite, 1973). The use of replacement estrogen treatment to control 
menopausal dysphoric symptoms is well known (Greenblatt, 1965), but there are few well 
controlled clinical studies in this area (Rose, 1972). It is conceivable that estrogens relieve 
the symptoms of some depressed post-menopausal women, while progesterone replacement 
might be more appropriate for those with irritability and anxiety. The prolactin concen- 
trations of post-menopausal women with and without dysphoric symptoms have yet to be 
studied. 
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Winokur & Cadoret (1975) have noted that episodes of primary affective disorder are not 
much more frequent at the menopause than at other age periods. This finding is reminiscent 
of Protheroe's work which indicated that serious post-partum depressions occurred in 
women with family loadings for affective disorder that were similar to those of women with 
non-puerperal depression (Protheroe, 1969). Both of these examples suggest that the 
hormonal changes at the puerperium or the menopause may be only one of a number of 
possible "triggers" for primary affective disorder in women with the requisite genetic 
loading. Nevertheless, they are identifiable events, subject to relatively easy experimental 
manipulation, which could enable us to understand their mechanism. 
We are not suggesting that there is a simple relationship between prolactin levels and 
affective change in women. We are in agreement with Smith (1975) who emphasized that the 
behavioral changes observed clinically are influenced by additional factors, such as heredity, 
previous personality, and individual susceptibility to hormonal changes in the central 
nervous system. We nevertheless believe that some of the clinical examples mentioned 
earher would be consistent with the suggestion that a dysphoric depressed mood may occur 
when high PRL levels are associated with low estrogen levels, whereas a dysphoric anxious 
or irritable mood may occur when high PRL levels are associated with low progesterone 
(Table I). Direct clinical testing of these ideas should be possible. 
TABLE I. SUGOESTED INTERACTIONS OF PROLACTIN, ESTROGEN AND 
PROGESTERONE IN RELATION TO AFFECTIVE CHAN(3B 
Prolact in  Es t rogen  Proges terone  
Premcns t rua l  depression High  Low N o r m a l  
Premenstrual anxiety- 
irritability-hostility High Normal Low 
Mid-cycle mood elevation High High Low 
Late pregnancy 
mood elevation High High High 
Post-partum depression High Low Low 
Menopausal dysphoria High(?) Low Low 
BEHAVIORAL EFFECTS OF PROLACTIN 
In keeping with the interactive roles that PRL is believed to have with other hormones, it 
seems that prolactin does not have major behavioral effects of its own. For example, 
patients with prolactin-secreting pituitary tumors, with idiopathic galactorrhoea and hyper- 
prolactinemia, and patients with isolated prolactin deficiency are not reported to show 
prominent behavioral disturbances (Gates, Fdesen & Samaan, 1973; Rolland, Schellekens 
& Leguin, 1974; Turkington, 1972). This is quite dissimilar from the situation in diseases of 
the pituitary-adrenal cortical system (Carroll, 1977). 
Some brief anecdotal reports have appeared that ovine prolactin injections can cause 
thirst, lethargy and irritability in humans (Greenwood, 1973; Horrobin, 1973a). McNeilly 
(1973) also reported that women with galactorrhoea and hyperprolactinemia "feel very 
much better in themselves" when PRL secretion is suppressed by bromocriptine. Despite 
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these few reports, the paucity of  observed clinical change in disorders involving PRL is 
remarkable. 
Behavioral effects of  PRL in animals are well known and have been reviewed by Nicoll 
(1974). The effects described are chiefly parental and nesting behavior in teleost fishes, 
birds and mammals,  together with migratory behavior in some species. There is also 
evidence that PRL may cause some of  its behavioral effects through a direct action on the 
brain. 
One obvious area for future study in animals and humans will be the interactions of  
prolactin with the behavioral effects of  adrenocortical and ovarian hormones. Prolactin is 
an unusual hormone, with over 85 reported actions in vertebrates. Nicoll (1973, 1974) has 
reviewed the animal studies which indicate that "synergisms between (or among) prolactin 
and steroid hormones (gonadal and adrenal cortical) are prominent features of  many of the 
physiological processes that are influenced (or regulated) by prolactin." In particular, there 
is much evidence that the temporal interactions of prolactin and ovarian or adrenal hor- 
mones are cri tcal  in determining the effect of  P R U  NicoU 0973) goes on to emphasize 
that " temporal  interactions among hormones should be given prime consideration in 
future analyses of  normal endocrine physiology and hormone-related pathologies." I t  is 
likely that there exist functional disorders related not so much to absolute hormone defi- 
ciency or excess, but rather to improper phasing among interacting hormones. 
This concept has been well established for some of the tissue effects of  prolactin. I t  is a 
somewhat new concept for behavioral endocrine research but its potential importance can 
hardly be overstated, particularly with respect to the periodic disorders (manic-depressive 
illness and periodic psychosis). The menstrual cycle provides an excellent model for the 
initial experimental study of  this concept in human behavioral pathology. 
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